We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    OSI-906-207
Previous Study | Return to List | Next Study

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01221077
Recruitment Status : Completed
First Posted : October 14, 2010
Last Update Posted : October 13, 2014
Information provided by (Responsible Party):
Astellas Pharma Inc

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : March 2013
  Study Completion Date : September 2014
  Certification or Request for Extension to Delay Results Submission: February 20, 2014